Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ITI-007 (Lumateperone Tosylate) for Schizophrenia

Trial Profile

ITI-007 (Lumateperone Tosylate) for Schizophrenia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2019 Status changed from planning to not yet recruiting.
    • 04 May 2017 New trial record
    • 01 May 2017 According to an Intra-Cellular Therapies media release, based on the responses regarding the nonclinical findings, US FDA may place hold on this trial. This trial will support an NDA approval for schizophrenia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top